KBI Biopharma vs ReciBioPharm: CDMO Comparison
How does KBI Biopharma compare to ReciBioPharm?
As of May 2026, KBI Biopharma: 2 FDA inspections (including 0 NAI, 2 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 84.1. ReciBioPharm: no FDA inspections on file, 3 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of KBI Biopharma and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- KBI Biopharma has FDA inspections on record (2); ReciBioPharm does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- ReciBioPharm has stronger MHRA / UK coverage (3 compliant certificates vs 1).
Across the cross-modality scorecard, KBI Biopharma carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: KBI Biopharma vs ReciBioPharm
How does KBI Biopharma compare to ReciBioPharm?
On CDMO Signal's composite Signal Score, KBI Biopharma is 84/100 and ReciBioPharm is 83/100; KBI Biopharma has 2 FDA inspections on record vs 0 for ReciBioPharm; European coverage is 1 active EMA+MHRA certificate for KBI Biopharma vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, KBI Biopharma or ReciBioPharm?
Both KBI Biopharma and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. KBI Biopharma has 2 FDA inspections on record; ReciBioPharm has 0.
How do KBI Biopharma and ReciBioPharm compare on European GMP coverage?
KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
KBI Biopharma carries a Signal Score of 84/100 and ReciBioPharm carries 83/100 — essentially tied for KBI Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →